https://www.selleckchem.com/products/U0126.html
6 months, = 0.005). Median progression-free survival was 6.3 months (95% CI, 4.6-8.. This study shows that combining irradiation with nivolumab for the treatment of advanced NSCLC leads to improved OS. The optimal time window for the combination of RT and immunotherapy seems to play a critical role for therapeutic antitumor response derived by abscopal effect. This study shows that combining irradiation with nivolumab for the treatment of advanced NSCLC leads to improved OS. The optimal time window for the combination of RT and immunoth
Like
Comment
Share
